RecruitingNCT05402839

Screening of Malignant Hyperthermia Susceptible Individuals

Molecular Genetics Study on Screening of Malignant Hyperthermia Susceptible Individuals


Sponsor

Peking University Third Hospital

Enrollment

50 participants

Start Date

Feb 22, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This study intends to target patients who underwent surgery under general anesthesia during the study period and developed malignant hyperthermia during or after surgery. Therefore, the total sample size was estimated to be about 50 people based on the past incidence of this rare disease. Every year, about 20 patients and their families who developed malignant hyperthermia during or after surgery will participate in this nationwide study (estimated by the current incidence of malignant hyperthermia), and about 1-5 patients will be admitted to Peking University Third Hospital participate in this research. Relevant specimens were collected from malignant hyperthermia (MH) patients and their family members for genetic analysis to determine the mutation of MH-related pathogenic gene loci.


Eligibility

Min Age: 0 YearsMax Age: 100 Years

Inclusion Criteria1

  • Patients undergoing surgery under general anesthesia during the study period developed malignant hyperthermia during or after surgery.

Exclusion Criteria2

  • Malignant hyperthermia was ruled out by later treatment and diagnosis;
  • The patient or family member refuses to be recruited.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Peking University Third Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05402839